awmsg logo



dexmedetomidine (Dexdor®)


Reference No. 661

Publication date:
13/08/2012


Last review date:
30/09/2016

Appraisal information

dexmedetomidine (Dexdor®) 100 micrograms/ml concentrate for solution for infusion


Company: Orion Pharma (UK) Ltd
BNF category: Anaesthesia
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2312
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Dexmedetomidine (Dexdor®) is recommended as an option for use within NHS Wales for the sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale [RASS] 0 to -3).
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download